Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staphylococcus Albicans Tablets in Bronchiectasis
NCT05407792Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of staphylococcus albus + neisseria catarrhalis in bronchiectasis (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoints: Number of acute exacerbations at 12 months, Time to first exacerbation at 12 months and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
staphylococcus albus + neisseria catarrhalis
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05407792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407792.